# Evaluation of the Efficacy and Safety of Nano-S1

> **NCT05822180** · PHASE3 · COMPLETED · sponsor: **General Administration of Military Health, Tunisia** · enrollment: 116 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** NANOS1 , argent colloïdal ,

## Key facts

- **NCT ID:** NCT05822180
- **Lead sponsor:** General Administration of Military Health, Tunisia
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-02-20
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2023-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05822180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05822180, "Evaluation of the Efficacy and Safety of Nano-S1". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05822180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*